Previous 10 | Next 10 |
Safety, tolerability and phospho-BTK inhibition at first three CG-806 dose levels in patients with CLL and other B-cell malignancies Plasma from CG-806 treated patients completely inhibited phospho-FLT3, suggesting current dose levels may be therapeutic in patients with AML New IN...
SAN DIEGO and TORONTO, June 02, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today an...
SAN DIEGO and TORONTO, May 14, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today annou...
SAN DIEGO and TORONTO, May 07, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the company will participate in and hold inv...
Image source: The Motley Fool. Aptose Biosciences (NASDAQ: APTO) Q1 2020 Earnings Call May 05, 2020 , 5:00 p.m. ET Operator Continue reading
Aptose Biosciences Inc. (APTO) Q1 2020 Earnings Conference Call May 5, 2020 05:00 PM ET Company Participants Susan Pietropaolo - SMP Communications William Rice - Chairman, President and CEO Gregory Chow - EVP and CFO Rafael Bejar - SVP and CMO Jotin Marango - SVP and CBO ...
Aptose Biosciences (NASDAQ: APTO ): Q1 GAAP EPS of -$0.15 misses by $0.05 . More news on: Aptose Biosciences Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
CG-806 Phase 1 a/b Study in B Cell Malignancies Now Dosing in Fourth Cohort CG-806 Proposed Starting Dose for Upcoming Phase 1 Study in AML Identified Conference Call and Webcast at 5pm EDT Today SAN DIEGO and TORONTO, May 05, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences I...
“The world is moving so fast these days that the man who says it can't be done is generally interrupted by someone doing it.” ― Elbert Hubbard A new medical development is sweeping the country… Some may see it as controversial - but the studies don’t ...
May 4, 2020 FN Media Group Presents Financialmorningpost.com Market Commentary New York, NY – May 4, 2020 – A new medical development is sweeping the country. Some may see it as controversial – but the studies don’t lie. It’...
News, Short Squeeze, Breakout and More Instantly...
Aptose Biosciences Inc. Company Name:
APTO Stock Symbol:
NASDAQ Market:
Aptose Biosciences Inc. Website:
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, t...
SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies,...
TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML TUS Monotherapy and TUS+VEN Doublet Therapy Active in...